The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Phesgo
pertuzumab, trastuzumab, and hyaluronidase-zzxf · PERTUZUMAB 1200 mg/15mL; TRASTUZUMAB 600 mg/15mL; HYALURONIDASE (HUMAN RECOMBINANT) 30000 U/15mL · Injection, Solution · Subcutaneous · Genentech, Inc.
NDC 50242-0245-86 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 15 mL in 1 VIAL, SINGLE-DOSE · BLA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- F. Hoffmann-La Roche AGSwitzerlandanalysis · label · manufacture · pack
- Genentech, Inc.United Statesanalysis
- Genentech, Inc.United Statesanalysis · api manufacture
- Roche Diagnostics GmbHGermanyanalysis
- Roche Diagnostics GmbHGermanyanalysis · api manufacture
- analysis · api manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 3 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $8,808.49 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA761170
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of pertuzumab, trastuzumab, and hyaluronidase-zzxf (Injection, Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Genentech, Inc. | PERTUZUMAB 1200 mg/15mL; TRASTUZUMAB 600 mg/15mL; HYALURONIDASE (HUMAN RECOMBINANT) 30000 U/15mL | Aug 26, 2026 | Sep 2, 2026 |
| Genentech, Inc. | PERTUZUMAB 600 mg/10mL; TRASTUZUMAB 600 mg/10mL; HYALURONIDASE (HUMAN RECOMBINANT) 20000 U/10mL | Aug 26, 2026 | Sep 2, 2026 |
| Genentech, Inc. | PERTUZUMAB 20000 U/10mL; TRASTUZUMAB 600 mg/10mL; HYALURONIDASE (HUMAN RECOMBINANT) 600 mg/10mL | Jul 22, 2026 | Aug 19, 2026 |
| Genentech, Inc. | PERTUZUMAB 30000 U/15mL; TRASTUZUMAB 1200 mg/15mL; HYALURONIDASE (HUMAN RECOMBINANT) 600 mg/15mL | Jul 22, 2026 | Aug 19, 2026 |
| Genentech, Inc. | HYALURONIDASE (HUMAN RECOMBINANT) 20000 U/10mL; PERTUZUMAB 600 mg/10mL; TRASTUZUMAB 600 mg/10mL | Jul 15, 2026 | Jul 15, 2026 |
| Genentech, Inc. | HYALURONIDASE (HUMAN RECOMBINANT) 30000 U/15mL; PERTUZUMAB 1200 mg/15mL; TRASTUZUMAB 600 mg/15mL | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Phesgo — NDC 50242-0245-86," retrieved September 3, 2026, https://drugdashboards.com/drug/50242024586.
Free to cite with attribution — see how the data is put together.